Bian Jingsong

School of Medicine
Department Head of Pharmacology


Dr. Jinsong Bian is a full Professor in the Department of Pharmacology, School of Medicine, Southern University of Science and Technology. He earned his PhD degree from the University of Hong Kong and was awarded the Dr KP Stephen Chang Gold Medal for outstanding performance in the degree of Doctor of Philosophy in 2000.  Dr Bian then went on to complete his post-doctoral training under an American Heart Association Fellowship at the Albert Einstein College of Medicine in New York, USA in 2003.

Dr Bian is an Associate Editor, lead guest editor and reviewing editor of 13 international journals, including Antioxidant Redox Signalling, Journal of Alzheimer’s Disease, Frontiers in Pharmacology. He has served as a panel member of the Singapore National Medical Research Council (since 2007) and is also a consultant Member of the Greece Society of Studying Cardiovascular Diseases (SOS-CVD) (since 2010). He serves as an advisory committee member of different societies or conferences, including the International and European Conferences on the Biology of Hydrogen Sulphide, and the Asian Society for Vascular Biology (ASVB). He has published over 120 papers in international journals including Cir Res, PNAS, JASN, Redox Biology, and has delivered over 70 lectures at the invitation of international and regional scientific societies, institutes and conference organizers.


Research Interests

  1. 1. Biology of endogenous mediators (e.g. hydrogen sulfide);

  2. 2. Novel functions of Na+/K+ ATPase.

Educational background

1997-2000    Ph. D.     Physiology, the University of Hong Kong.

1990-1993    M. Sci.     Pharmacology, Nanjing Medical University, P. R. China.

1985-1990:   MBBS      Medicine, Xuzhou Medical University, P. R. China.


Professional experience

2020.5-Present: Department Head of Pharmacology,Professor,Southern University of Science and Technology, Shenzhen

2009.01-2020.4: Associate Professor (with Tenure), Department of Pharmacology,  Yong Loo Lin school of Medicine, National University of Singapore

2003.10-2008.12:Assistant Professor in Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2000.5—2003.9: Research Associate and AHA fellow in Section of Molecular Cardiology and Department of Molecular Pharmacology, Albert Einstein College of Medicine, USA

1993.7 – 1997.3: Assistant Professor and lecturer in Department of Pharmacology, School of Basic Medical Science, Nanjing Medical University, China


Honors & Awards

2017      Research Excellence Award (AY2015/2016), Yong Loo Lin School of Medicine, National university of Singapore

2001      AHA fellowship, American Heart Association, New York affiliate

2000   Dr. KP Stephen Chang Gold Medal, the University of Hong Kong

2000      Mary Sun Scholarship 1999/2000, the University of Hong Kong

1999      Wong Ching Yee Medical Postgraduate Scholarship, the University of Hong Kong

1999   Prof. A.C. Brown Prize, the 7th Physiology Annual Meeting

1998   Certificate of Merit, the University of Hong Kong.


Professional Activities

2010-Present  Review Editor & Editorial Board Member, Frontiers in Pharmacology

2010-Present  Review Editor and Editorial Board Member: Frontiers in Clinical and Translational Physiology

2011-Present:  Editorial board member, Journal of Pharmacological Sciences

2015-2016:   Reviewing Editor, Antioxidant Redox Signalling

2015-2016:   Lead guest editor, Oxidative Medicine and Cellular Longevity

2010-2011    Associate Editorship, Journal of Alzheimer’s Disease

2010-2012    Editorial Board Member, Biomed Central-Medical Gas Research

2009-present    Editorial Board Member, World Journal of Cardiology

2010-present    Lead guest editor, Journal Biochemistry Research International

2011-present:Editorial board member: World Journal of Hypertension

2010-present    Editorial Board Member, Journal of Geriatric Cardiology

2013-2018    Editor Board Member, Journal of Zhongshan University


Selected publications

1. Sun HJ, Cao L, Zhu MY, Wu ZY, Shen CY, Nie XW, Bian JS*. DR-region of Na+/K+-ATPase is a target to ameliorate hepatic insulin resistance in obese diabetic mice. Theranostics, 2020, Accepted.

2. Zhu M, Cao L, Xiong S, Sun H, Wu Z, Bian JS. Na+/K+-ATPase-dependent autophagy protects brain against ischemic injury. Signal Transduction and Targeted Therapy. 2020, Accepted.

3. Sun HJ, Xiong SP, Wu ZY, Cao L, Zhu MY, Moore PK, Bian JS. Induction of caveolin 3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy. Redox Biology, 2020, Mar 5;32:101493. doi: 10.1016

4. Sun HJ, Lee WT, Leng B, Wu ZY, Yang Y, Bian JS. Nitroxyl as a Potential Theranostic in the Cancer Arena. Antioxid Redox Signal. 2020 Feb 10;32(5):331-349. doi: 10.1089/ars.2019.7904.

5. Cao X, Ding L, Xie ZZ, Yang Y, Whiteman M, Moore PK, Bian JS. A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer? Antioxid Redox Signal. 2019 Jul 1;31(1):1-38.

6. Shi M, Cao L, Cao X, Zhu M, Zhang X, Wu Z, Xiong S, Xie Z, Yang Y, Chen J, Wong PTH, Bian JS. DR-region of Na+/K+ ATPase is a target to treat excitotoxicity and stroke. Cell Death Dis. 2018 Dec 18;10(1):6. doi: 10.1038/s41419-018-1230-5.

7. Cao X, Nie X, Xiong S, Cao L, Wu Z, Moore  PK, Bian JS. Renal protective effect of polysulfide in cisplatin-induced nephrotoxicity. Redox Biology, 2018 May;15:513-521.

8. Cao L, Cao X, Zhou Y, Vijay NB, Wu ZY, Hu LF, Yang Y, Sethi G, Moore PK, Bian JS. Hydrogen sulfide inhibits ATP-induced neuroinflammation and Aβ1-42 synthesis by suppressing the activation of STAT3 and cathepsin S. Brain Behav Immun. 2018 Oct;73:603-614.

9. Cao X, Xiong S, Zhou Y, Wu ZY, Ding L, Zhu Y, Wood M, Whiteman M, Moore PK, Bian JS. Renal protective effect of hydrogen sulfide in cisplatin-induced nephrotoxicity. Antioxid Redox Signal. 2018 Jan 9. doi: 10.1089/ars.2017.7157. [Epub ahead of print]

10. Nie X, Tan J, Dai Y, Liu Y, Zou J, Sun J, Ye S, Shen C, Fan L, Chen J, Bian JS.  CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation. J Mol Cell Cardiol. 2018 Mar;116:41-56